Glenmark Pharma gets approval from USFDA for Colesevelam Hydrochloride

17 Jul 2018 Evaluate

Glenmark Pharmaceuticals, USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Colesevelam Hydrochloride for Oral Suspension, 1.875 grams/Packet and 3.75 grams/Packet, the generic version of Welchol for Oral Suspension, 1.875 grams/Packet and 3.75 grams/Packet, of Daiichi Sankyo Inc.

According to IQVIA sales data for the 12 month period ending May 2018, Welchol for Oral Suspension, 1.875 grams/Packet and 3.75 grams/Packet achieved annual sales of approximately $73.0 million.

The company’s current portfolio consists of 138 products authorized for distribution in the US marketplace and 62 ANDA’s pending approval with the USFDA.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).

Glenmark Pharma Share Price

2000.60 -10.90 (-0.54%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×